secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001140361-26-002200
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart
---------------------------------------------------------------------------

- Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.
- Adds navenibart (Phase 3 plasma kallikrein inhibitor) offering every-3/6-month HAE dosing.
- Astria CEO Jill Milne joins BioCryst board; John Ruesch becomes Chief Technical Operations Officer.
- BioCryst obtained $400M term loan from Blackstone funds (5-yr, SOFR+4.5% with PIK option).
- Astria's nine-month 2025 net loss $98.4M; had $227.7M cash/investments at Sep 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/0001140361-26-002200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/ef20063492_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-002200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer